Revenue
$7.12M
Gross Margin
+99.5%
Operating Margin
-670.2%
Net Margin
-339.3%
Income statement waterfall for Ovid Therapeutics (OVID) — TTM through Q1 2026
Net income: −$24.17M
Margin breakdown for Ovid Therapeutics (OVID) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Revenue | $7.12M | $7.12M |
| Cost of Revenue | −$35.00K | $7.09M |
| Gross Profit | $7.09M | $7.09M |
| Operating Expenses | −$54.82M | −$47.73M |
| Operating Income | −$47.73M | −$47.73M |
| Other Income / Expense | $23.57M | −$24.17M |
| Pre-tax Income | −$24.17M | −$24.17M |
| Income Tax | $0.00 | −$24.17M |
| Net Loss | −$24.17M | −$24.17M |
- Revenue$7.12M
- Cost of Revenue−$35.00K
- Gross Profit$7.09M
- Operating Expenses−$54.82M
- Operating Income−$47.73M
- Other Income / Expense$23.57M
- Pre-tax Income−$24.17M
- Income Tax$0.00
- Net Loss−$24.17M
Want to see what changed vs last year?Profit Bridge
Frequently asked questions
Data & methodology
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement